PT-141, also known as bremelanotide, is a synthetic cyclic peptide that acts as an agonist at melanocortin receptors. It is a derivative of the melanotan-II scaffold and is used in research as a probe of the melanocortin signaling system, particularly the central MC4R subtype.
A melanocortin-system tool
PT-141 engages melanocortin receptors — notably MC4R — making it a useful tool for dissecting central melanocortin signaling, distinct from the pigmentation-focused effects of melanotan-II. This focus gives researchers a way to study one branch of a broad receptor family.
Its structure
PT-141 is a constrained cyclic heptapeptide; the lactam ring that defines it is described in its structure and synthesis. That ring favors the conformation associated with melanocortin-receptor engagement.
Its mechanism
Details of receptor engagement are covered in its mechanism of action. Because it is a defined peptide, interpreting its sequence follows general amino acid sequence principles.
Relationship to melanotan-II
Much of PT-141's research value comes from being compared to its broader-acting relative, a lineage summarized in its discovery and history.
Research context
As with all research compounds, reproducibility depends on documented purity — see how to read a COA. Findings describe laboratory behavior only.
What researchers can compare
Because PT-141 is closely related to melanotan-II but has a different terminal form and receptor emphasis, the pair supports controlled structure–activity comparisons. Receptor-defined assays can examine binding, cAMP signaling, and response timing under matched conditions. These experiments are most informative when receptor expression is measured directly rather than inferred from the name of a cell line or tissue preparation.
Boundaries of the research record
Evidence from one melanocortin agonist should not be assigned automatically to another, even when they share a cyclic core. Sequence termini, ring chemistry, purity, and model context can all alter observed behavior. PT-141 should therefore be discussed as a specific molecular entity, with conclusions limited to in-vitro and preclinical systems and without converting receptor findings into usage guidance. Terminology should remain exact: receptor agonism describes a measured molecular interaction and downstream response in an experimental system, not a general prediction for every biological setting. Receptor subtype expression, assay amplification, and peptide integrity all shape the observation. Clear reporting allows the same compound to serve as a reproducible reference across different melanocortin models.
Product page: PT-141 research vials.
Research Use Only. Supplied strictly for laboratory research and development — not for human or veterinary use, consumption, or any therapeutic or diagnostic purpose. This article is research education, not usage guidance.